Navigation Links
Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Date:9/7/2012

CHAPEL HILL, N.C., Sept. 7, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Sept. 9 to 12.  The data will further delineate the clinical profile and activity spectrum of solithromycin, the company's late clinical-stage fluoroketolide antibiotic candidate.  The data demonstrate the promising safety and tolerability profile of solithromycin as well as a pharmacokinetic-pharmacodynamic (PK-PD) analysis that will be used to support Phase 3 intravenous (IV) dose selection.  Solithromycin's activity spectrum was further defined by demonstrating superior activity against Canadian isolates of Neisseria gonorrhoeae compared to azithromycin and the first study investigating solithromycin's activity against Treponema pallidum.   

"Data presented at this year's conference are geared to further detailing the profile of solithromycin from both clinical and activity perspectives," said Prabhavathi Fernandes, president and chief executive officer of Cempra.  "The data should be helpful when we analyze the results from our IV Phase 1 trial, which we expect to complete in the second half of 2012, and our Phase 2 trial in patients with uncomplicated gonococcal infections, which we expect to complete in the fourth quarter of this year, and in the preparation of our Phase 3 program in community-acquired bacterial pneumonia, which we expect to begin in the fourth quarter of this year."

Solithromycin safety and tolerability continues to appear promising

Solithromycin has demonstrated a favorable safety and tolerability profile when compar
'/>"/>

SOURCE Cempra Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UAS Laboratories Presents about Probiotic Selection Criteria, at Scientific Conference
2. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
3. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
4. In Comes the Non-Toxic Rust Remover; Rusterizer Presents Its Rust Removal Product Made With Natural Ingredients
5. Fusion presents low proliferation risk, experts conclude
6. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
7. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
8. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
9. ODT Forum Presents Regenerative Technologies
10. Fusion presents low proliferation risk, experts conclude
11. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... May 12 Aton Pharma, Inc., a global,specialty ... a,distribution agreement with Meizler Biopharma S/A to commercialize,CUPRIMINE(R) ... in,Brazil, and Meizler is working to obtain regulatory ... medically essential products, and Aton is,committed to making ...
... Poised to Impact Lung Cancer Care, ST. ... medical,device start-up company, has secured $4.75M in venture ... IG4 delivery system for minimally,invasive biopsy and ablation ... and was joined by Advantage Capital Partners and ...
... (NYSE:,CVD) today announced that it will present at the ... 2008 at 10:30 am ET. Investors may,access a live ... order to,register and download any necessary software, please log ... New Jersey, is one of the,world,s largest and most ...
Cached Biology Technology:Aton Pharma Announces Distribution Partnership in Brazil 2Veran Medical Technologies Secures $4.75M in First Institutional Funding 2
(Date:8/19/2014)... Research and Network-Level Science, , Imagine if we had ... ecosystems was responding to global changes in real time. ... coupled multiple decades of information about ecological responses to ... dozens of different ecosystem types. , In fact, ... (LTER) Network, which will soon celebrate its 35th anniversary. ...
(Date:8/19/2014)... leprosy and tuberculosis live side-by-side. Worldwide there are ... with nearly all of them occurring where tuberculosis ... Calmette-Guerin, or BCG, provides only partial protection against ... vaccine is needed to combat both diseases. UCLA-led ... both diseases., In a study published in the ...
(Date:8/19/2014)... devised a new implantable tissue scaffold coated with bone ... weeks. When applied to bone injuries or defects, this ... bone that looks and behaves just like the original ... a dramatic improvement over the current standard for treating ... of the patient,s body a painful process that ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... within weeks after a person is infected with the HIV ... Center and the Bernard-Nocht Institute appearing in the international open-access ... mostly found in the digestive tract, tend not to return ... In recent years, HIV infection has been shown to deplete ...
... Oct. 2 tells a tale of "genome archaeology" by ... of maize and rice. Their resulting insights into plant ... genetically modified organism (GMO) controversy. , "Our findings elucidate ... much like modern biotechnologists do. Now we must reassess ...
... the December issue of the journal Cell Metabolism, published ... which the mammary glands of mammals meet the incredible ... of breast development undoubtedly affect breast cancer, the findings ... researchers found that one of three “isoforms?of the gene ...
Cached Biology News:Early HIV treatment fails to restore memory T cells 2Genome archaeology illuminates the genetic engineering debate 2How mammals fuel milk production may have implications for cancer 2How mammals fuel milk production may have implications for cancer 3
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
... and miRNA Isolation Traditional mRNA isolation ... and can result in the loss of ... miRNA Isolation Kit purifies all RNA species ... Through an enrichment procedure included in the ...
Biology Products: